MA24401A1 - Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin - Google Patents

Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin

Info

Publication number
MA24401A1
MA24401A1 MA24864A MA24864A MA24401A1 MA 24401 A1 MA24401 A1 MA 24401A1 MA 24864 A MA24864 A MA 24864A MA 24864 A MA24864 A MA 24864A MA 24401 A1 MA24401 A1 MA 24401A1
Authority
MA
Morocco
Prior art keywords
intemedary
substituted
preparation
pyridines used
pyridines
Prior art date
Application number
MA24864A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA24401A1 publication Critical patent/MA24401A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA24864A 1996-11-14 1997-11-11 Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin MA24401A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
MA24401A1 true MA24401A1 (fr) 1998-07-01

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24864A MA24401A1 (fr) 1996-11-14 1997-11-11 Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin

Country Status (32)

Country Link
US (1) US6291489B1 (fr)
EP (1) EP0938476B1 (fr)
JP (1) JP3510635B2 (fr)
KR (1) KR20000053314A (fr)
CN (1) CN1237160A (fr)
AP (1) AP805A (fr)
AR (1) AR010584A1 (fr)
AT (1) ATE319687T1 (fr)
AU (1) AU4634697A (fr)
BG (1) BG103393A (fr)
BR (1) BR9712951A (fr)
CA (1) CA2270386C (fr)
CO (1) CO4930261A1 (fr)
DE (1) DE69735433D1 (fr)
EA (1) EA199900375A1 (fr)
GT (1) GT199700118A (fr)
HR (1) HRP970612A2 (fr)
ID (1) ID18898A (fr)
IL (1) IL129688A0 (fr)
IS (1) IS5029A (fr)
MA (1) MA24401A1 (fr)
MY (1) MY132507A (fr)
NO (1) NO992296D0 (fr)
OA (1) OA11044A (fr)
PA (1) PA8441401A1 (fr)
PE (1) PE10299A1 (fr)
TN (1) TNSN97172A1 (fr)
TR (1) TR199901063T2 (fr)
UY (1) UY24774A1 (fr)
WO (1) WO1998021184A1 (fr)
YU (1) YU22099A (fr)
ZA (1) ZA9710186B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042518A (ko) * 1998-04-08 2001-05-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 신규 제초제
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
EP1153919A4 (fr) * 1999-02-16 2002-10-02 Kaneka Corp Derives d'acetylpyridine substituee et procede de preparation d'intermediaires pour agoniste du recepteur adrenergique beta3 optiquement actif, faisant appel a ces derives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
EP1078924B1 (fr) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermédiaires et un procédé pour la préparation des agonistes du récepteur beta3-adrénergique [2000/16]
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ （Ｓ）−α−ハロメチルピリジンメタノール誘導体の製造方法
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
WO2003072573A1 (fr) 2002-02-27 2003-09-04 Pfizer Products Inc. Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
RU2313524C2 (ru) 2003-05-09 2007-12-27 Ф.Хоффманн-Ля Рош Аг МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
WO1994029290A1 (fr) * 1993-06-14 1994-12-22 Pfizer Inc. Amines secondaires utilisees comme agents antidiabete et anti-obesite
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
EP0828712A1 (fr) * 1995-05-10 1998-03-18 Pfizer Inc. Agonistes du recepteur beta-adrenergique
US5977124A (en) * 1995-05-10 1999-11-02 Pfizer Inc. β-adrenergic agonists

Also Published As

Publication number Publication date
NO992296L (no) 1999-05-12
CA2270386A1 (fr) 1998-05-22
BG103393A (en) 2000-07-31
PA8441401A1 (es) 2000-05-24
HRP970612A2 (en) 1998-08-31
WO1998021184A1 (fr) 1998-05-22
JP2000504347A (ja) 2000-04-11
YU22099A (sh) 2001-09-28
DE69735433D1 (de) 2006-05-04
JP3510635B2 (ja) 2004-03-29
AP9701147A0 (en) 1998-01-31
CA2270386C (fr) 2004-08-03
UY24774A1 (es) 1998-05-05
AU4634697A (en) 1998-06-03
PE10299A1 (es) 1999-02-10
AP805A (en) 2000-01-28
KR20000053314A (ko) 2000-08-25
MY132507A (en) 2007-10-31
OA11044A (en) 2002-02-20
CO4930261A1 (es) 2000-06-27
US6291489B1 (en) 2001-09-18
ZA9710186B (en) 1999-05-12
GT199700118A (es) 1999-05-05
EP0938476B1 (fr) 2006-03-08
EP0938476A1 (fr) 1999-09-01
EA199900375A1 (ru) 1999-12-29
TR199901063T2 (xx) 1999-08-23
TNSN97172A1 (fr) 2005-03-15
IS5029A (is) 1999-04-16
NO992296D0 (no) 1999-05-12
CN1237160A (zh) 1999-12-01
ID18898A (id) 1998-05-20
IL129688A0 (en) 2000-02-29
ATE319687T1 (de) 2006-03-15
AR010584A1 (es) 2000-06-28
BR9712951A (pt) 1999-12-07

Similar Documents

Publication Publication Date Title
MA24401A1 (fr) Procede pour la preparation de pyridines substitues et intemediaires utilisees a cette fin
MA23611A1 (fr) Procede pour la synthese de sulfoxydes substitues
RO91184A (fr) Procede pour la preparation des derives de 2,2'-iminobisethanol
MA24426A1 (fr) Procede pour la preparation de nouveaux composes
EP0738424A4 (fr) Procede et structure de passivation pour circuit integre
MA20880A1 (fr) Procede pour la preparation de derives de thienoimidazole substitues
MA21983A1 (fr) Procede pour la preparation de derives de quinolone .
FR2654332B1 (fr) Appareillage pour stomie.
MA24427A1 (fr) Procede pour la preparation de nouveaux composes
FR2509300B1 (fr) Derives d'azetidinone et procede pour leur preparation
RO93218A (fr) Procede pour la preparation des derives de 2-oxyndole
FR2687687B1 (fr) Procede pour mesurer la taille de fragments d'adn.
RO96413A (fr) Procede pour la preparation des derives de thoadiazole
MA24319A1 (fr) Procedes et intermediaires pour la preparation de derives de chromanol substitues
MA23900A1 (fr) Procede pour la preparation de compositions antiretrovirale
MA21984A1 (fr) Procede pour la preparation de derives de quilinone .
FR2647446B1 (fr) Procede pour la preparation selective de 1,4-diamino-2-nitrobenzenes substitues en n4
FR2559771B1 (fr) Derives de la 3-pyrrolidinopropiophenone et procede pour leur preparation
FR2663173B1 (fr) Circuit d'attenuation et procede d'etalonnage pour ce circuit.
FI904680A7 (fi) Menetelmä ja laite folioiden "kylmäsyvävetämiseksi"
MA24245A1 (fr) Procede pour la preparation de nouveaux composes sulfonylures
FR2555578B1 (fr) Procede de preparation de derives d'azetidinone
FR2731365B1 (fr) Tensioactif glycolipidique et procede pour sa preparation
FR2551079B1 (fr) Compositions perfectionnees pour la dissolution de metaux et procede de dissolution
FR2549042B1 (fr) Procede pour la preparation de la 3,11-dimethyl-2-nonacosanone